Risk factors of death or chronic renal replacement therapy requirements in patients with thrombotic microangiopathies without ADAMTS-13 deficiency.

Autor: Uriol-Rivera MG; Nephrology Department, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain.; Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Andrade BL; Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain.; Hematology Department, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Bonet AM; Radiology Department, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Mulet AO; Nephrology Department, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain.; Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Ruiz CB; Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain.; Hematology Department, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Parraga LP; Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain.; Pharmacy Department, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Lumbreras J; Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain.; Pediatric Nephrology Department, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Rota JIA; Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain.; Intensive Care Unit, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Servalos MF; Intensive Care Unit, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Balaguer JF; Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain.; Immunology Department, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Ferreres LP; Internal Medicine Department, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Valles MJP; Radiology Department, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Valero RMRG; Gynecology and Obstetrics Department, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Sanchez ST; Neurology Department, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Martin AG; Neurology Department, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Garcia JR; Preventive Medicine Department, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Cobo CG; Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain.; Clinical Analysis, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain., Ramis-Cabrer D; Fundació Institut d'Investigació Sanitària Illes Balears (IdISBa), Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain.

Publikováno v: European journal of haematology [Eur J Haematol] 2024 Oct; Vol. 113 (4), pp. 510-520. Date of Electronic Publication: 2024 Jul 02.

Safety assessment for Tris(2,4-di-tert-butylphenyl) phosphite (Irgafos 168) used as an antioxidant and stabilizer in food contact applications.

Autor: Markley LC; Division of Food Contact Substances, Office of Food Additive Safety, Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, 5001 Campus Drive, HSF-275, College Park, MD, 20740, USA. Electronic address: Laura.Markley@fda.hhs.gov., González Bonet AM; Division of Food Contact Substances, Office of Food Additive Safety, Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, 5001 Campus Drive, HSF-275, College Park, MD, 20740, USA., Ogungbesan A; Division of Food Contact Substances, Office of Food Additive Safety, Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, 5001 Campus Drive, HSF-275, College Park, MD, 20740, USA., Bandele OJ; Division of Food Contact Substances, Office of Food Additive Safety, Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, 5001 Campus Drive, HSF-275, College Park, MD, 20740, USA., Bailey AB; Division of Food Contact Substances, Office of Food Additive Safety, Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, 5001 Campus Drive, HSF-275, College Park, MD, 20740, USA., Patton GW; Division of Food Contact Substances, Office of Food Additive Safety, Center for Food Safety and Applied Nutrition, U.S. Food and Drug Administration, 5001 Campus Drive, HSF-275, College Park, MD, 20740, USA.

Publikováno v: Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association [Food Chem Toxicol] 2023 Aug; Vol. 178, pp. 113877. Date of Electronic Publication: 2023 Jun 17.